To the Editor: Increasingly, the practice of medicine has relied on applicable and available evidence to deliver quality care. Cardiovascular medicine has led the way using numerous clinical trials as the basis of clinical practice guidelines. However, despite the strong association of aging with the development of cardiovascular disease, randomized clinical trials rarely enroll a substantial proportion of older adults, leading experts to question the applicability of the evidence base to the typical patient with cardiovascular disease (1) . We sought to document the inclusion of older adults in contemporary highprofile, recently conducted clinical trial populations in cardiovascular disease and compare the age characteristics of the clinical trials with the age characteristics of the diseases being studied.
All late-breaking clinical trials (LBCTs) at the 2011 American Heart Association (AHA) Scientific Sessions were included in this study (2) . For each LBCT, a brief summary of the important results, with all available age information, was extracted. This represented inclusion or exclusion characteristics on the basis of age and the age information of the baseline characteristic (means, medians, and proportions above and below age cut points). The LBCTs were divided into disease-based categories, and results were tabulated by category. When available, the published report for each LBCT was used. In cases in which the reports were not published, information was obtained from the LBCT slide set on the AHA Web site (2) and supplemented with information from ClinicalTrials.gov as needed. To compare the clinical trial cohort with the community population, the prevalence of older adults in each disease category was ascertained.
The 22 LBCTs at the 2011 AHA Scientific Sessions were divided by category: coronary artery disease (5 trials), acute coronary syndromes (5), chronic heart failure (3), atrial fibrillation (3), cardiac surgery and intervention (4), peripheral artery disease (1), and venous thromboembolism (1). Among those trials, 8 did not include older adults (age Ͼ60 to 80 years, depending on the study). In trials in which the percents of older adults were available, adults age Ͼ75 years constituted 9% to 55% of the enrolled subjects. In the remaining trials, the mean age was 54 to 66 years. This contrasts with the prevalence of older age among those with cardiovascular diseases in the general population, in which older adults represent one-third to one-half of patients with the cardiovascular diseases studied in these trials. See Table 1 for details.
With aging of the United States population and the evolving demographics of cardiovascular disease, we reviewed the LBCTs at the 2011 AHA Scientific Sessions to determine the ages of enrolled subjects and, when available, the percent of older adults included each trial. Our findings show that in the current era of clinical cardiovascular research, the demographics of those enrolled in the LBCTs are inconsistent with those of the community population and inadequately represent older adults with cardiovascular disease.
This report is not the first to raise concern about the enrollment of older adults in clinical trials in cardiovascular disease (26) . Lee et al. (27) documented the low representation of older adults in randomized trials of acute coronary syndromes. Kitzman and Rich (28) identified the low percent of older adults in heart failure research in comparison with the advanced ages of most patients with heart failure. The gap in the evidence base for cardiovascular care in older adults has led experts to call for a new paradigm in the way we provide cardiac care and in the way we study cardiovascular disease (1) . Nonetheless, this review of LBCTs at the 2011 AHA Scientific Sessions confirms that current high-profile cardiovascular clinical research still does not address the challenges of an aging society.
There are several disadvantages to systematically excluding older adults from clinical trials. When caring for older adults, we are forced to apply therapies that have not been proven effective in this vulnerable population. Second, by failing to enroll older and more complicated patients, the generalizability of the trial results to the broad population can be questioned. If a therapy shows a small benefit in the context of a highly selected clinical trial population, how can we reliably translate those results to the patients we care for, young and old?
In conclusion, the enrollment of older adults in the LBCTs at the 2011 AHA Scientific Sessions is low and does not reflect the representation of older adults with cardiovascular disease in the general population. Despite multiple calls to generate more agespecific data to better guide management for the older adults most vulnerable to cardiovascular disease and to cardiovascular disease management complexities, this need is still not being prioritized in cutting-edge, premier cardiovascular research efforts. 
